Cargando…
Efficacy and Safety of ACE Inhibitor and Angiotensin Receptor Blocker Therapies in Primary Focal Segmental Glomerulosclerosis Treatment: A Systematic Review and Meta-Analysis
RATIONALE AND OBJECTIVE: Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker therapy (renin-angiotensin-aldosterone system [RAAS] inhibitor) to control proteinuria in primary and genetic focal segmental glomerulosclerosis (FSGS) follows guidelines based on other proteinuria-relat...
Autores principales: | Campbell, Kirk N., Pennese, Natali, Zaffalon, Andrea, Magalhaes, Barbara, Faiella, Marina, Caster, Dawn J., Radhakrishnan, Jai, Tesar, Vladimir, Trachtman, Howard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065901/ https://www.ncbi.nlm.nih.gov/pubmed/35518835 http://dx.doi.org/10.1016/j.xkme.2022.100457 |
Ejemplares similares
-
Efficacy and Safety of Immunosuppressive Therapy in Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis
por: Caster, Dawn J., et al.
Publicado: (2022) -
Remission of post-transplant focal segmental glomerulosclerosis with angiotensin receptor blockers
por: Bansal, S. B., et al.
Publicado: (2017) -
Molecular Mechanisms of Proteinuria in Focal Segmental Glomerulosclerosis
por: Wen, Yumeng, et al.
Publicado: (2018) -
Novel Treatment Paradigms: Focal Segmental Glomerulosclerosis
por: de Cos, Marina, et al.
Publicado: (2022) -
Complement Activation in Patients with Focal Segmental Glomerulosclerosis
por: Thurman, Joshua M., et al.
Publicado: (2015)